BlackRock’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-3,734,188
| Closed | -$129M | – | 5271 |
|
|
2020
Q3 | $129M | Sell |
3,734,188
-191,932
| -5% | -$4.09M | ﹤0.01% | 1722 |
|
|
2020
Q2 | $65.6M | Buy |
3,926,120
+296,166
| +8% | +$5.03M | ﹤0.01% | 2099 |
|
|
2020
Q1 | $52.3M | Sell |
3,629,954
-46,941
| -1% | -$1.2M | ﹤0.01% | 2016 |
|
|
2019
Q4 | $123M | Buy |
3,676,895
+54,338
| +1% | +$1.52M | ﹤0.01% | 1843 |
|
|
2019
Q3 | $75.9M | Buy |
3,622,557
+79,402
| +2% | +$1.62M | ﹤0.01% | 2051 |
|
|
2019
Q2 | $73.8M | Sell |
3,543,155
-167,221
| -5% | -$3.44M | ﹤0.01% | 2100 |
|
|
2019
Q1 | $82.9M | Sell |
3,710,376
-12,735
| -0.3% | -$300K | ﹤0.01% | 1986 |
|
|
2018
Q4 | $89.1M | Sell |
3,723,111
-259,469
| -7% | -$6.71M | ﹤0.01% | 1878 |
|
|
2018
Q3 | $109M | Buy |
3,982,580
+338,740
| +9% | +$9.58M | ﹤0.01% | 1915 |
|
|
2018
Q2 | $98M | Buy |
3,643,840
+565,410
| +18% | +$17.3M | ﹤0.01% | 1950 |
|
|
2018
Q1 | $98M | Buy |
3,078,430
+334,618
| +12% | +$11.8M | ﹤0.01% | 1864 |
|
|
2017
Q4 | $104M | Sell |
2,743,812
-28,196
| -1% | -$910K | ﹤0.01% | 1858 |
|
|
2017
Q3 | $68.7M | Buy |
2,772,008
+158,400
| +6% | +$3.41M | ﹤0.01% | 2082 |
|
|
2017
Q2 | $53.7M | Buy |
2,613,608
+471,719
| +22% | +$9M | ﹤0.01% | 2208 |
|
|
2017
Q1 | $46.5M | Buy |
2,141,889
+2,139,355
| +84,426% | +$43.9M | ﹤0.01% | 2269 |
|
|
2016
Q4 | $52K | Sell |
2,534
-115
| -4% | -$2.35K | ﹤0.01% | 2916 |
|
|
2016
Q3 | $40K | Buy |
2,649
+1,695
| +178% | +$22.9K | ﹤0.01% | 3076 |
|
|
2016
Q2 | $10K | Buy |
954
+494
| +107% | +$6.71K | ﹤0.01% | 3415 |
|
|
2016
Q1 | $6K | Buy |
+460
| New | +$7.18K | ﹤0.01% | 3351 |
|
BlackRock's AIMT Position: Q4 2020 in Review
BlackRock sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 3,734,188 shares — an estimated $129M sold.
BlackRock first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $129M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- BlackRock reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- BlackRock sold 3,734,188 Aimmune Therapeutics shares in Q4 2020, an estimated $129M.
- BlackRock first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
- BlackRock's Aimmune Therapeutics position peaked at $129M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on BlackRock's 13F filing for Q4 2020, filed 5 Feb 2021.